BioNTech (NASDAQ:BNTX) Trading Up 2.7%

BioNTech SE (NASDAQ:BNTX)’s stock price was up 2.7% during mid-day trading on Monday . The stock traded as high as $88.93 and last traded at $88.85. Approximately 546,858 shares traded hands during trading, a decline of 17% from the average daily volume of 658,333 shares. The stock had previously closed at $86.48.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BNTX shares. BMO Capital Markets reduced their target price on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a research note on Thursday, March 21st. Oppenheimer started coverage on BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating for the company. JPMorgan Chase & Co. decreased their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a report on Friday, March 22nd. HC Wainwright cut their target price on BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research note on Tuesday, January 23rd. Finally, UBS Group decreased their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $120.40.

BioNTech Stock Up 0.2 %

The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $91.67 and a two-hundred day simple moving average of $97.64. The stock has a market capitalization of $20.57 billion, a P/E ratio of 20.77 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. Equities research analysts forecast that BioNTech SE will post -1.67 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds have recently modified their holdings of the company. Wealthcare Advisory Partners LLC acquired a new position in BioNTech in the first quarter worth $242,000. Park Avenue Securities LLC bought a new position in shares of BioNTech in the first quarter valued at about $201,000. American National Bank acquired a new position in BioNTech during the 1st quarter worth about $81,000. Green Alpha Advisors LLC grew its holdings in BioNTech by 12.9% during the 1st quarter. Green Alpha Advisors LLC now owns 5,819 shares of the company’s stock worth $537,000 after acquiring an additional 666 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.